Introduction
The immune escape of tumor cells and successful tumor outgrowth may be due to the inability of the immune system to react to the tumor. Despite the expression of tumor rejection antigens, such as MAGE 1-3 [1] [2] [3] , and the presence of tumor-specific cytotoxic T cells [2] , the immune system fails to contain gastric carcinoma. The evidence suggests that a poor local immune response contributes to the potential for lymph nodal metastatic spread of gastric tumors [3] . This mechanism by which gastric cancers overcome antitumor immunological responses is poorly understood.
Fas ligand (FasL) is produced by activated T cells and natural killer (NK) cells, and it induces apoptosis in target cells through the death receptor Fas/Apo1/CD95 [4] [5] [6] [7] [8] [9] . One important role of FasL-Fas systems is to mediate immune-cytotoxic killing of cells that are harmful to the organism, such as virus-infected or tumor cells [10, 11] . The involvement of FasL and Fas as a possible mechanism whereby tumors escape the immune system has recently been proposed. As one of the mechanisms, a "Fas counterattack" model of tumor immune escape was proposed, in which a cancer cell, by expressing FasL, may remove Fas-sensitive immune effector cells by apoptosis. Evidence for this mechanism of tumor immune privilege by "Fas counterattack" has since been provided for several cancers; gastric carcinoma [12] , melanoma [13] , hepatocellular carcinoma [14] , lung cancer [15] , astrocytoma [16] , colon cancer [17] , and liver metastasis of colon adenocarcinoma [18] have been shown to express FasL. On the other hand, some reports suggest that other immune escape mechanisms allowed the eventual establishment of tumors without the Fas system [19] [20] [21] .
As to the mechanism by which the FasL function is controlled, it was recently reported that there is a soluble decoy receptor (DcR3) [22, 23] , which binds to FasL and inhibits FasL-induced apoptosis. DcR3, a member of the tumor necrosis factor receptor (TNFR) superfamily, shares sequence identity in particular with osteoprotegerin (31%) [24] and TNFR 2 (29%), and has relatively less homology with Fas (17%). The DcR3 gene was amplified in about half of primary lung and colon cancers [22] , and was overexpressed in human adenocarcinomas of gastrointestinal tract regions [25] , suggesting that certain tumors may escape FasLdependent immune-cytotoxic attack by expressing a decoy receptor which blocks FasL. DcR3 is expressed in the fetal brain, lung, and liver, and in the adult spleen, lung, and colon, and maps to chromosome position 20q13, which is the amplicon in various cancers [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
To evaluate whether DcR3 has clinical relevance in actual human gastric cancers, we investigated the expression of the DcR3 gene by Northern blot analysis in primary gastric carcinomas, compared with the clinicopathological features and prognosis.
Patients and methods

Patients and tissue samples
Tissue specimens taken from 84 gastric cancer patients who underwent operations at the First Department of Surgery, Nara Medical University, from January 1991 to December 1997, were used. Cancerous tissues and the respective noncancerous tissues adjacent to tumor areas were frozen immediately after surgical removal, in liquid nitrogen, and stored at Ϫ80°C for subsequent Northern blot analysis. The histological types, numbers, and pathological stages of the primary gastric cancers, as well as the patients' sex, are shown in Table 1 . The pathological stage was classified according to the tumornode-metastasis classification of gastric carcinoma of the Union Internationale Contre Cancer. The Lauren classification was used for histological type .
Preparation of cDNA probes
A human DcR3 cDNA sequence was obtained by reverse transcription-polymerase chain reaction (RT-PCR) amplification and used as a probe. Briefly, human spleen polyA RNA (Clontech, Palo Alto, CA, USA) was reverse-transcribed to cDNA with an oligodeoxythymidylic acid primer and then poly-A selected. The resultant cDNA was subjected to PCR to amplify the human DcR3 fragment. The first PCR primer sequences were: 5Ј-CTACTGCAACGTCCTCTGT-3Ј for the forward primer and 5Ј-TGGAGATGTCCTGG AAAGGCC-3Ј for the reverse primer. The nested PCR primers were: 5Ј-CTACTGCAACGTCCTCTGT-3Ј for the forward primer and 5Ј-ACAGGGTGTCATGGG AGGAA-3Ј for the reverse primer. The PCR conditions were: 10 min at 95°C for preheating; 30 cycles of 1 min of denaturation at 95°C, 1 min of annealing at 65°C, 40 s of extension at 72°C; and 10-min post- 
Northern blot analysis
Total RNA was extracted from cancerous and noncancerous stomach tissues using an Isogen kit (Nippon Gene, Toyama, Japan). Twenty-microgram aliquots were electrophoresed in 1% agarose-formaldehyde gels, transferred to nylon membranes (Hybond N plus; Amersham, Buckinghamshire, UK), and hybridized with 1 ϫ 10 6 cpm/ml of a 32 P-radiolabeled DcR3 cDNA probe, prepared using a DNA Labeling Kit (d-CTP) (Pharmacia Biotech, Uppsala, Sweden), in Rapid-hyb buffer (Amersham) and 100 µg/ml salmon testis DNA at 65°C for 2 h. Membranes were washed in 2ϫ standard saline citrate (SSC) and 0.1% sodium dodecylsulfate (SDS) at room temperature for 15 min and twice in 0.2ϫ SSC and 0.1% SDS at 65°C for 15 min. The DcR3 expression level was then analyzed and quantified densitometrically with a BAS 1000 image analyzer (Fuji Photo Film, Tokyo, Japan). Next, membranes were exposed to Scientific Imaging Film (Kodak; Rochester, NY, USA) with an intensifying screen overnight at Ϫ80°C. After the exposure, the Northern blots were reprobed with a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe to confirm that similar amounts of RNA were loaded and transferred from each sample. Within each sample, the density of the DcR3 mRNA band was determined by comparing the densities of the GAPDH bands. We categorized DcR3 overexpression in cancerous tissues when the density was more than two fold enhanced compared with the values derived from the respective noncancerous samples.
Preparation of riboprobes
Digoxygenin-labeled sense or antisense riboprobes were synthesized by T3 or T7 RNA polymerase from cDNA plasmids containing entire coding sequences of human DcR3 cDNA, in the presence of digoxygenindUTP (Boehringer-Mannheim, Mannheim, Germany).
In situ hybridization
In situ hybridization experiments, using fresh frozen tissue sections and digoxygenin-labeled riboprobes, were carried out. Gastric tissues were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) at 4°C for 12 h, then dehydrated in 30% sucrose in PBS at 4°C for 4 h, with gentle agitation, and then embedded in OCT and sectioned at a thickness of 10 µm. The sections were immediately dried at 45°C for 3 h. Before hybridization, the slides were soaked in 0.2 N HCl for 20 min to inactivate endogenous alkaline phosphatase, rinsed with deionized water, treated with proteinase K for 10 min at 37°C, hydrated with ethanol, and then air dried. An appropriate amount of the probe in 50 µl of hybridization buffer, consisting of 300 mM NaCl, 30 mM sodium citrate, 50% v/v deionized formamide, 1% w/v SDS, 50 µg/ml heparin, and 50 µg/ml yeast RNA, was applied to each slide, and hybridization was carried out at 65°C for 12 h. After hybridization, the slides were washed with 300 mM NaCl-sodium citrate and 50% deionized formamide at 52°C for 1 h. Detection was carried out with an anti-digoxygenin antibody conjugated with alkaline phosphatase. Colorimetric reaction with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-1-phosphate was carried out at room temperature for 48 h. As the re-ference, methyl green staining was performed in serial sections.
Statistical analyses
DcR3 expression in relation to pathological stage, histological type, and cancer cell differentiation was analyzed for significance, using the 2 test. Overall survival periods were calculated by the Kaplan-Meier method, and the data were evaluated with the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model, with StatView statistical software (Abacus Concepts, Berkeley, CA, USA).
Results
Cloning of DcR3 cDNA
Human DcR3 cDNA was obtained by RT-PCR amplification. Human spleen polyA RNA was reverse transcribed to cDNAs, then the cDNAs were subjected to PCR to amplify the human DcR3 cDNA fragment. A 1-µl aliquot of the first PCR reaction mixture was used for the nested PCR under the same PCR conditions. We obtained a 313-bp cDNA segment and confirmed the cDNA segment to be a DcR3 cDNA by sequence analysis.
DcR3 overexpression was associated with lymph node metastasis and pathological stage
In 84 patients recently operated for gastric cancer, paired samples of tumor and noncancerous stomach tissue were subjected to Northern blot analysis, using the cDNA probe for DcR3. The patient distribution is listed in Table 1 . DcR3 expression was detected in both tumor and noncancerous stomach tissue. Representative results of the Northern blot analysis are shown in Fig. 1a . In all instances, cancerous tissue was compared with the respective noncancerous tissues adjacent to the tumor areas in the same patient. This comparison is important, because, although DcR3 mRNA was found to be expressed in all normal stomach tissues examined, the absolute level of DcR3 expression varies among individuals. The relative level of DcR3 mRNA expression in the 84 paired samples (noncancerous and cancerous tissues) was quantified by densitometric scanning of Northern blots and normalized to the signal obtained by hybridizing to GAPDH mRNA (Fig. 1b) . DcR3 mRNA was overexpressed in 22 (26%) primary gastric carcinomas compared with each noncancerous tissue. The expression of DcR3 was analyzed in comparison with the clinicopathological features. The following factors were considered: sex, age, tumor status, lymph node involvement, systemic metastasis, histological type, and stage. As shown in Table 1 , there were no significant differences in sex, age, tumor status, systemic metastasis, and histological type between the DcR3 expression levels. However, DcR3 expression in cancerous tissue was significantly increased in lymph node metastasispositive patients (35%) in comparison with lymph node metastasis-negative patients (11%; P ϭ 0.03). With respect to clinical stage, DcR3 expression status also had a significant association. Specifically, 8.7% of stage 1 tumors and 32.8% stage 2-4 tumors had DcR3 overexpression (P ϭ 0.02). Thus, DcR3 overexpression in cancerous tissue was significantly associated with lymph node metastasis and pathological stage, but did not correlate with any other factors at a statistically significant level. The localization of DcR3 in gastric carcinoma tissue was confirmed by in situ hybridization, using a DcR3 antisense RNA probe. DcR3 expression was seen in tumor cells (Fig. 2a) , whereas DcR3 expression was very weak or undetectable in stromal cells and noncancerous tissue (Fig. 2b) . In contrast, the sense RNA probe did not show any signal (Fig. 2c) .
Prognostic significance of DcR3 overexpression for survival
The prognostic significance of DcR3 expression for patient survival was evaluated by univariate analysis (logrank test). In the entire group of gastric cancer patients, when followed up for 63 months, DcR3 overexpression in cancerous tissue was found to be associated with a significantly shortened duration of overall survival compared with that in patients whose cancerous tissue expressed a normal level of DcR3 (Fig. 3) (P ϭ 0.016). Tumor status, lymph vessel invasion, and lymph node involvement were also factors associated with poor survival.
Multivariate analysis was carried out to further evaluate whether DcR3 would serve as an independent factor to predict patient outcome. As shown in Table 2 , tumor status and lymph node involvement, but not DcR3 overexpression, were independent prognostic factors for survival. Fig. 1 . a Northern blot analysis for DcR3 mRNA in representative gastric cancer cases. Twenty micrograms of total RNA extracted from cancerous and noncancerous stomach tissues was electrophoresed in 1% agarose-formaldehyde gels, transferred to a nylon membrane, and hybridized with a 32 P-radiolabeled DcR3 cDNA probe. The densities of each band were measured using a BAS 1000 image analyzer, and the density of the DcR3 mRNA band was determined by comparing the densities of GAPDH bands. DcR3 overexpression was considered to be shown in cancerous tissues when the density was more than twofold enhanced compared with values derived from the respective non-cancerous samples. b mRNA overexpression in cancerous tissue is evident for some tumors, as compared with noncancerous stomach tissue. Numbers, Patient numbers; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; N, Noncancerous tissue; T, tumor tissue
Discussion
FasL is a member of the tumor necrosis factor family [4] [5] [6] [7] [8] [9] and mediates apoptosis in many cell types, including both transformed and nontransformed cells [4, 5, 10, 11] .
FasL has been shown to play a crucial role in lymphocyte cytotoxicity [38] [39] [40] and is also important in mediating autocrine suicide in activated T lymphocytes [41] [42] [43] [44] . The involvement of FasL and Fas as a possible mechanism whereby tumors escape the immune system has recently been proposed. A "Fas counterattack" model of tumor immune escape was proposed, in which a cancer cell, by expressing FasL, may remove Fassensitive immune effector cells by apoptosis. Evidence for this mechanism of tumor immune privilege by "Fas counterattack" has since been provided for several cancers; gastric carcinoma [12] , melanoma [13] , hepatocellular carcinoma [14] , lung cancer [15] , astrocytoma [16] , In the entire group of gastric cancer patients, when followed up for 63 months, DcR3 overexpression in cancerous tissue was found to be associated with a significantly shortened duration of overall survival compared with that in patients whose cancerous tissue expressed a normal level of DcR3 (P ϭ 0.016) colon cancer [17] , and liver metastasis of colon adenocarcinoma [18] have been shown to express FasL. On the other hand, some reports do not support a role for FasL expression in the escape of tumors from immune destruction; overexpression of FasL does not confer immune privilege to a pancreatic beta tumor cell line [19] ; human melanoma cell lines do not express FasL [20] ; and the Fas system is not significantly involved in apoptosis in human hepatocellular carcinoma [21] . These reports indicate that there may be other mechanisms of tumor immune escape besides Fas counterattack. Tumor cells have been shown to prevent a T-cell immune response by various means, including downregulation of MHC class I molecules [45, 46] , lack of co-stimulative signals such as B7 [47, 48] , secretion of immunoinhibitory proteins such as transforming growth factor (TGF)- [49] , loss of signal transducing chains from tumor-infiltrating lymphocytes [50] [51] [52] , and the interaction of neoplastic cells with the inhibitory CTLA-4 receptor [53] .
The DcR3 gene, a member of the TNFR superfamily, was recently reported to be a soluble decoy receptor, which binds to FasL and inhibits FasL-induced apoptosis. The DcR3 gene was amplified in about half of primary lung and colon cancers [22] and was overexpressed in human adenocarcinomas of gastrointestinal tract regions [25] , which suggested that certain tumors may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL. To evaluate whether DcR3 has clinical relevance in actual human gastric cancers, we investigated the expression of the DcR3 gene in primary gastric carcinomas. In this report, we have shown that some stomach cancers overexpress DcR3, an inhibitor of immunocyte apoptosis.
DcR3 overexpression by gastric cancerous tissue was significantly associated with lymph node metastasis, but did not correlate with any other factors, such as tumor status and systemic metastasis. DcR3 overexpression in cancerous tissue was found to be associated with a significantly shortened duration of overall survival compared with that in patients whose cancerous tissue expressed normal levels of DcR3, by univariate analysis, but DcR3 overexpression was not an independent prognostic factor for survival by multivariate analysis. Tumor status, lymph vessel invasion, and lymph node involvement were the factors associated with poor survival. These results indicate that DcR3 overexpression may be involved mainly in lymph vessel and node invasion of tumors, by inhibiting FasL-induced apoptosis through activated T cells and NK cells in patients with gastric carcinomas.
Cancerous tissue contains both cancer cells and normal stomach tissue, so it may be that the adjacent normal epithelial cells or stromal cells overexpress DcR3.
The evidence shows that, in the analysis of DcR3 expression in squamous cell carcinoma of the lung by in situ hybridization, DcR3 mRNA was localized to the infiltrating malignant epithelium, but was essentially absent from adjacent stroma [22] . To detect the localization of DcR3 mRNA in gastric carcinoma tissue, we performed in situ hybridization, using the DIG Nuclear Acid Detection Kit (Roche Molecular Biochemicals, Mannheim, Germany). DcR3 mRNA was expressed in tumor cells, but DcR3 expression was very weak in stromal cells and noncancerous tissue.
The DcR3 gene maps to chromosome position 20q13 [22] , which is the amplicon in various cancers; breast cancer [26] [27] [28] , colorectal carcinoma [29, 30] , renal cell carcinoma [31] , prostate cancer [32] , uroepithelial cells [33] , ovarian cancer [34] , astrocytic tumor [35] , chondrosarcomas [36] , and gastric carcinoma [37] . These results suggest that there are essential genes on 20q13 which are concerned with the malignant potential of tumors, indicating that DcR3 may be one of the candidate genes in the progression not only of gastric cancer but also of other organ carcinomas.
Our findings conclusively show, at the mRNA level, that some human gastric cancers overexpress DcR3. Gastric cancer may therefore be added to the growing list of malignancies that appear to be immunologically prevalent through DcR3 overexpression. The high prevalence of DcR3 expression in the tumors suggests that this molecule may be critical to tumor immune privilege. It has not been evaluated whether or not DcR3 is identified in sera. If circulating forms of DcR3 are also increased in the blood in cancer patients, this could contribute to the generalized depression of cellular immunity seen in patients with neoplastic disease. In conclusion, the DcR3 decoy receptor for FasL may be involved in the progression of gastric cancer. Further evaluation of these possible roles of DcR3 and the regulation of DcR3 expression in malignant cells will be critically important for the development of new strategies for controlling the growth of malignant cells that escape host immune surveillance.
